First Affiliated Hospital of Gannan Medical University

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Wnt5a/Ca2+ signal promotes myogenic differentiation by mediating a slow and sustained influx of Ca2+

The extracellular Ca 2+ is crucial for the regeneration of skeletal muscles, but there is still uncertainty regarding the channels through which it enters the cells. The purpose of this study is to investigate how the Wnt5a/Ca²⁺ signaling pathway promotes myogenic differentiation...